Effects of a SARS-associated coronavirus vaccine in monkeys - PubMed (original) (raw)

Effects of a SARS-associated coronavirus vaccine in monkeys

Wentao Gao et al. Lancet. 2003.

Abstract

The causative agent of severe acute respiratory syndrome (SARS) has been identified as a new type of coronavirus. Here, we have investigated the ability of adenoviral delivery of codon-optimised SARS-CoV strain Urbani structural antigens spike protein S1 fragment, membrane protein, and nucleocapsid protein to induce virus-specific broad immunity in rhesus macaques. We immunised rhesus macaques intramuscularly with a combination of the three Ad5-SARS-CoV vectors or a control vector and gave a booster vaccination on day 28. The vaccinated animals all had antibody responses against spike protein S1 fragment and T-cell responses against the nucleocapsid protein. All vaccinated animals showed strong neutralising antibody responses to SARS-CoV infection in vitro. These results show that an adenoviral-based vaccine can induce strong SARS-CoV-specific immune responses in the monkey, and hold promise for development of a protective vaccine against the SARS causal agent.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Western blot analysis of immunised (1699, 1201, 1401, 11300, 13601 and 15101) and control (1901 and 2001) monkeys Bands indicate presence of S1-specific antibodies in serum.

Figure 2

Figure 2

Nucleocapsid-specific T-cell responses (upper) and neutralising capacity (lower) of serum samples after vaccination Immunised animals represented by black symbols, controls by white symbols. (Upper) ELISPOT analysis 24 h after monkey peripheral blood mononuclear cells (PBMC) were incubated with pools of nucleocapsid-specific peptides and interferon-γ (IFN-γ) spot-forming cells (SFC) were counted. Data are mean (SE) of triplicate determinations after subtraction of background responses. (Lower) Detection of virus-specific neutralising antibodies in serum by inhibition of E6 Vero cell lysis by SARS-CoV strain Urbani in a microneutralisation assay. Data for 1699 and 1201 overlap at all time points.

References

    1. Rota PA, Oberste MS, Monroe SS. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300:1394–1399. - PubMed
    1. Anton IM, Gonzalez S, Bullido MJ. Cooperation between transmissible gastroenteritis coronavirus (TGEV) structural proteins in the in vitro induction of virus-specific antibodies. Virus Res. 1996;46:111–124. - PMC - PubMed
    1. Brown K, Gao W, Alber S, etal. Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent siv-specific t-cell immunity in monkeys. J Immunol (in press). - PubMed
    1. Weiss RC, Scott W. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis. 1981;4:175–189. - PMC - PubMed
    1. Fouchier RA, Kuiken T, Schutten M. Aetiology: Koch's postulates fulfilled for SARS virus. Nature. 2003;423:240. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources